BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 22418018)

  • 1. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.
    Ravelli A; Grom AA; Behrens EM; Cron RQ
    Genes Immun; 2012 Jun; 13(4):289-98. PubMed ID: 22418018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Boom V; Anton J; Lahdenne P; Quartier P; Ravelli A; Wulffraat NM; Vastert SJ
    Pediatr Rheumatol Online J; 2015 Dec; 13():55. PubMed ID: 26634252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.
    Yasin S; Schulert GS
    Curr Opin Rheumatol; 2018 Sep; 30(5):514-520. PubMed ID: 29870499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
    Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
    Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.
    Wagner-Weiner L
    Pediatr Ann; 2015 Jun; 44(6):e142-7. PubMed ID: 26114369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
    Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and correct diagnosis of macrophage activation syndrome.
    Cron RQ; Davi S; Minoia F; Ravelli A
    Expert Rev Clin Immunol; 2015; 11(9):1043-53. PubMed ID: 26082353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
    Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
    World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
    Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
    J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Minoia F; Bovis F; Davì S; Horne A; Fischbach M; Frosch M; Huber A; Jelusic M; Sawhney S; McCurdy DK; Silva CA; Rigante D; Unsal E; Ruperto N; Martini A; Cron RQ; Ravelli A;
    Ann Rheum Dis; 2019 Oct; 78(10):1357-1362. PubMed ID: 31296501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches.
    Bruck N; Schnabel A; Hedrich CM
    Clin Immunol; 2015 Jul; 159(1):72-83. PubMed ID: 25956529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis.
    Avau A; Put K; Wouters CH; Matthys P
    Cytokine Growth Factor Rev; 2015 Feb; 26(1):35-45. PubMed ID: 24948570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
    Naveen R; Jain A; Muhammed H; Gupta L; Misra DP; Lawrence A; Agarwal V; Misra R; Aggarwal A
    Rheumatol Int; 2021 Mar; 41(3):625-631. PubMed ID: 33388903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performances of the "MS-score" And "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.
    Sag E; Keskin A; Atalay E; Demir S; Cuceoglu MK; Akca UK; Batu ED; Bilginer Y; Ozen S
    Rheumatol Int; 2021 Jan; 41(1):87-93. PubMed ID: 33215249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Gorelik M; Fall N; Altaye M; Barnes MG; Thompson SD; Grom AA; Hirsch R
    J Rheumatol; 2013 Jul; 40(7):1191-9. PubMed ID: 23678162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage activation syndrome in the era of biologic therapy.
    Grom AA; Horne A; De Benedetti F
    Nat Rev Rheumatol; 2016 May; 12(5):259-68. PubMed ID: 27009539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Bracaglia C; de Graaf K; Pires Marafon D; Guilhot F; Ferlin W; Prencipe G; Caiello I; Davì S; Schulert G; Ravelli A; Grom AA; de Min C; De Benedetti F
    Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
    Yasin S; Fall N; Brown RA; Henderlight M; Canna SW; Girard-Guyonvarc'h C; Gabay C; Grom AA; Schulert GS
    Rheumatology (Oxford); 2020 Feb; 59(2):361-366. PubMed ID: 31326996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation syndrome and cytokine-directed therapies.
    Schulert GS; Grom AA
    Best Pract Res Clin Rheumatol; 2014 Apr; 28(2):277-92. PubMed ID: 24974063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.
    Schulert GS; Grom AA
    Annu Rev Med; 2015; 66():145-59. PubMed ID: 25386930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.